Metis Techbio-p logo

Metis Techbio-p

7666.HK

HKSEHealthcareBiotechnology

Latest quote

HK$13.53

−HK$0.71 · -4.99%

Aug 24, 11:01 AM HKT

7666.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Metis TechBio Co., Ltd., founded in 2020 and headquartered in Beijing, China, (previously Hangzhou Jitai Pharmaceutical Technology Co., Ltd.) specializes in the advanced research and development of AI-powered nanomaterials. The company's core mission is to facilitate the delivery and application of active agents within carbon-based life forms, operating in both the Chinese Mainland and the United States. Central to its offerings is NanoForge, a comprehensive suite of interconnected technologies that includes a novel lipid library, foundational artificial intelligence models, METiSAIAgent, cutting-edge quantum chemistry and molecular dynamics simulations, and AI-driven screening platforms. Furthermore, Metis TechBio has developed specialized platforms like AiTEM, AiLNP, and AiRNA. These tools are crucial for simulating, predicting, and interpreting interactions at the nanoscale, thereby enabling the precise design, optimization, and validation of sophisticated nanomaterials and their associated payloads. The company provides its services through a three-tiered system: a foundational dry-wet data layer supported by integrated laboratory infrastructure, a model layer featuring METiS AI foundational models, and an application layer known as METiSAgentv. Metis TechBio primarily serves a diverse clientele, including pharmaceutical companies, biotechnology firms, and medical research institutions.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CN
CEO
Tsai-Ta Lai
Listed since
May 13, 2026
Employees
5

Market position

Day range

Current HK$13.53

52-week range

Current HK$13.53

Open
HK$14.79
Previous close
HK$14.24
Volume
3.97M
0.85× average
Average volume
4.68M
Average daily volume
Market cap
16B HKD
Beta
2.15
Market reference 1
50-day average
HK$12.3898
+9.20% above average
200-day average
HK$13.742
-1.54% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-37.36×
P/B (TTM)
13.71×
P/S (TTM)
139.56×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
66.01%
Operating margin
-367.07%
Net margin
-373.18%

Financial health

Debt / equity
0.13×

Earnings

Latest fiscal-year EPS
-0.046
FY2025
Latest fiscal-year revenue
14.63M HKD
FY2025 · +6974.88% year over year
Next fiscal-year EPS consensus
-0.087
FY2026 · 2 analysts
Next fiscal-year revenue consensus
428.41M HKD
FY2026 · 3 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend0.340.11-0.13-0.36FY23FY24FY25FY26FY27FY28

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend1.1B701.46M300.74M-99.97MFY23FY24FY25FY26FY27FY28

7666.HK peers

Continue in GoAI

Research 7666.HK

research.disclaimer